Credit Suisse Group set a €71.00 ($82.56) price target on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note released on Thursday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.
Other equities research analysts have also issued research reports about the stock. HSBC set a €101.00 ($117.44) price target on shares of Grenke and gave the stock a buy rating in a report on Thursday, April 25th. Nord/LB set a €92.00 ($106.98) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a report on Friday, May 3rd. Berenberg Bank reissued a buy rating and issued a GBX 100 ($1.31) price target on shares of in a report on Thursday, July 11th. Independent Research set a €74.00 ($86.05) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a neutral rating in a report on Monday, June 17th. Finally, Morgan Stanley boosted their price target on shares of WPP from GBX 1,025 ($13.39) to GBX 1,060 ($13.85) and gave the stock an equal weight rating in a report on Wednesday. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Fresenius Medical Care AG & Co. KGaA has an average rating of Buy and a consensus target price of €82.57 ($96.01).
Shares of ETR FME opened at €67.00 ($77.91) on Thursday. The stock has a market cap of $20.45 billion and a price-to-earnings ratio of 10.43. The business has a fifty day moving average of €68.38. The company has a debt-to-equity ratio of 100.05, a quick ratio of 0.67 and a current ratio of 1.02. Fresenius Medical Care AG & Co. KGaA has a one year low of €55.44 ($64.47) and a one year high of €91.74 ($106.67).
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading: How to invest in a bear market
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.